Ryan Chen, Ph.D. MBA’s Post

Day 1 -Insights in drug discovery : Leveraging insilico docking and column chromatography techniques from 21st October, 2024 to 30 October, 2024 has been inaugurated today. In VIPER https://lnkd.in/gcBrtqEt

Are molecular glues the key to undruggable targets?   In case you missed it, Dr Benedict CS Cross spoke with Labiotech.eu about the growing interest in the field of molecular glues and the potential for this new modality to open up immense new possibilities in degrader drug development. Read the full article here: https://rb.gy/pnzjdu   #MolecularGlues #DrugDiscovery #DrugDevelopment

‼️ UPCOMING BIG NEW TOY FOR THE LAB ‼️ Holodiag is proud to announce the acquisition of an electron diffractometer: the ELDICO ED-1. Becoming the first company in Europe having such an equipment, we warmly thank ELDICO Scientific AG and particularly Danny Stam for his professional skills and the high level technical discussions. As part of Icrom Srl and Proxis Developpement, this investment is entirely in line with the group's desire to develop its pharmaceutical entity. The ELDICO ED-1 diffractometer will be deployed for the resolution of crystal structure and elucidation of molecular structure. All are critical steps for drug development and quality assurance. ➡️ Interested in crystal structure resolution and/or molecular structure elucidation ? All you need is a grain of powder... and Holodiag 😉 The delivery is expected Q2 2025. More content to come about electron diffraction, stay tuned! #molecularstructure #crystalstructure #pharma

‼️ UPCOMING BIG NEW TOY FOR THE LAB ‼️ Holodiag is proud to announce the acquisition of an electron diffractometer: the ELDICO ED-1. Becoming the first company in Europe having such an equipment, we warmly thank ELDICO Scientific AG and particularly Danny Stam for his professional skills and the high level technical discussions. As part of Icrom Srl and Proxis Developpement, this investment is entirely in line with the group's desire to develop its pharmaceutical entity. The ELDICO ED-1 diffractometer will be deployed for the resolution of crystal structure and elucidation of molecular structure. All are critical steps for drug development and quality assurance. ➡️ Interested in crystal structure resolution and/or molecular structure elucidation ? All you need is a grain of powder... and Holodiag 😉 The delivery is expected Q2 2025. More content to come about electron diffraction, stay tuned! #molecularstructure #crystalstructure #pharma

We are here at the Emergence of Irreversible Modulation in Drug Discovery conference in Cambridge! 🧬💊 Stop by our booth today and tomorrow (October 16-17) to chat with Timothy Orwell about how we can support your drug discovery journey. 📖 Learn More: https://lnkd.in/eYV2eKFp #DrugDiscovery #IrreversibleModulation #Spectroscopy

‼️ UPCOMING BIG NEW TOY FOR THE LAB ‼️ Holodiag is proud to announce the acquisition of an electron diffractometer: the ELDICO ED-1.   Becoming the first company in Europe having such an equipment, we warmly thank ELDICO Scientific AG and particularly Danny Stam for his professional skills and the high level technical discussions. As part of Icrom Srl and Proxis Developpement, this investment is entirely in line with the group's desire to develop its pharmaceutical entity.   The ELDICO ED-1 diffractometer will be deployed for the resolution of crystal structure and elucidation of molecular structure. All are critical steps for drug development and quality assurance.   ➡️ Interested in crystal structure resolution and/or molecular structure elucidation ? All you need is a grain of powder... and Holodiag 😉   The delivery is expected Q2 2025. More content to come about electron diffraction, stay tuned! #molecularstructure #crystalstructure #pharma

At WADC in London our team presented a poster showcasing our unique ThioBridge™ conjugation technology that's been proven to improve the stability, potency and efficacy of antibody-drug conjugates (#ADCs).   ThioBridge™ addresses key challenges in ADC design and development by leveraging naturally occurring interchain disulfide bonds. This results in a more uniform drug-to-antibody ratio (DAR) profile, improved linker stability and precise site-specificity, ensuring no deconjugation or cross-conjugation issues.   Biopharma developers: How might this technology impact your ADC pipeline? Let's discuss the potential for improved efficacy and safety profiles today!   Access the poster here to learn more: https://lnkd.in/eU8p5ima

How can you generate data for 125,000 interactions from a fragment-based or target-focused small-molecule library…in just three days?  Find out in our free webinar on December 11, 2024, to be hosted in collaboration with Carna Biosciences, Inc..   HT-SPR is a direct, label-free method that produces gold-standard, real-time kinetics for highly parallel interactions. In this webinar, we highlight the power of combining an extensive panel of biotinylated kinases with small-molecule fragment and target-focused libraries to generate a wealth of compound binding information that can augment the drug discovery process for this challenging class of drug targets.   ➡ Register here and save your spot: https://bit.ly/3AlmBSQ   #HTSPR #kinases #drugdiscovery #labelfree #webinar #smallmolecule #Carterra

Fragment-Based Screening is usually performed on only one or two targets at a time.  High-throughput SPR can increase that to over 100 simultaneous screens providing high-definition data and faster decision making.    Our latest poster, in collaboration with Carna Biosciences, Inc., shows how combining Carterra SPR arrays with an off-the-shelf biotinylated kinase panel enabled collection of 125,000 unique fragment/protein interactions in just three days. This binding and selectivity data can be used early in the drug discovery process to help identify off-target toxicity for this class of targets.   We presented this poster at the recent Drug Discovery Chemistry in Barcelona. If you missed it, check it out here: https://lnkd.in/dygVYTsa   #fragmentscreening #kinases #HTSPR #labelfree #drugdiscovery #DDCEurope